(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) **EP 3 417 294 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
04.05.2022 Bulletin 2022/18

(45) Date of publication and mention of the grant of the patent:
01.12.2021 Bulletin 2021/48

(21) Application number: **17753704.0**

(22) Date of filing: **14.02.2017**

(51) International Patent Classification (IPC):
C07K 16/28 *(2006.01)* ***G01N 33/574*** *(2006.01)*
A61K 38/00 *(2006.01)* ***A61P 35/00*** *(2006.01)*
A61K 31/502 *(2006.01)* ***A61K 31/506*** *(2006.01)*
A61K 45/06 *(2006.01)* ***A61K 48/00*** *(2006.01)*
A61P 9/10 *(2006.01)* ***A61P 43/00*** *(2006.01)*
A61K 39/395 *(2006.01)*

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
C07K 16/2827; A61K 31/502; A61K 31/506; A61K 39/39558; A61K 45/06; A61K 48/00; A61P 9/10; A61P 35/00; A61P 43/00 (Cont.)

(86) International application number:
PCT/US2017/017804

(87) International publication number:
WO 2017/142871 (24.08.2017 Gazette 2017/34)

(54) **METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB**

VERFAHREN MIT FIXER INTERMITTIERENDER DOSIERUNG VON CEDIRANIB

PROCÉDÉS COMPRENANT UN DOSAGE INTERMITTENT ET FIXE DE CEDIRANIB

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(30) Priority: **15.02.2016 US 201662295421 P**

(43) Date of publication of application:
26.12.2018 Bulletin 2018/52

(60) Divisional application:
21211394.8

(73) Proprietors:
- **Astrazeneca AB**
  151 85 Södertälje (SE)
- **The United States of America, as Represented By the Secretary, Department of Health and Human Services**
  Bethesda, MD 20892 (US)

(72) Inventors:
- **BARRY, Simon**
  Cambridge CB4 0WG (GB)
- **KENDREW, Jane**
  Macclesfield
  Cheshire SK10 4TG (GB)
- **HO, Tony**
  Gaithersburg, MD 20878 (US)
- **WEDGE, Stephen, Robert**
  Granta Park
  Cambridge CB21 6GH (GB)
- **IVY,Susan Percy**
  Bethesda, MD 20892-7660 (US)
- **KOHN, Elise**
  Bethesda, MD 20892-7660 (US)
- **LEE, Jung-Min**
  Bethesda, MD 20892-7660 (US)

(74) Representative: **Finnegan Europe LLP**
1 London Bridge
London SE1 9BG (GB)

(56) References cited:
WO-A1-2006/035203 US-A1- 2014 377 285

Processed by Luminess, 75001 PARIS (FR)

(Cont. next page)

- **JOYCE F LIU ET AL: "A randomised phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer.", THE LANCET ONCOLOGY, vol. 15, no. 11, 1 October 2014 (2014-10-01), pages 1207-1214, XP055490379, AMSTERDAM, NL ISSN: 1470-2045, DOI: 10.1016/S1470-2045(14)70391-2**
- **KIERAN MARK W ET AL: "A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors", CHILD'S NERVOUS SYSTEM, vol. 31, no. 9, 19 July 2015 (2015-07-19), pages 1433-1445, XP035541345, SPRINGER, BERLIN, DE ISSN: 0256-7040, DOI: 10.1007/S00381-015-2812-5 [retrieved on 2015-07-19]**
- **CHARLES J RYAN ET AL: "Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC)", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, vol. 25, no. 5, 26 April 2007 (2007-04-26) , pages 445-451, XP019526142, KLUWER ACADEMIC PUBLISHERS, BO ISSN: 1573-0646, DOI: 10.1007/S10637-007-9050-Y**
- **LEE JUNG-MIN ET AL: "Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 35, no. 19, 1 July 2017 (2017-07-01), pages 2193-2202+9pp, XP002792437, ISSN: 1527-7755**
- **LIU, JF et al.: "A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer", European Journal of Cancer, vol. 49, no. 14, September 2013 (2013-09), pages 2972-2978, XP055410070,**
- **WEBSTER, RM: "Combination therapies in oncology", Nature Reviews., vol. 15, no. 2, 6 February 2016 (2016-02-06), pages 81-82, XP055410072,**
- **"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube", Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer, October 2016 (2016-10), XP055575178, Retrieved from the Internet: URL:https://clinicaltrials.gov/ct2/show/study/NCT01116648 [retrieved on 2017-04-03]**

(52) Cooperative Patent Classification (CPC): (Cont.)

C-Sets
A61K 31/502;
A61K 31/506;
A61K 39/39558